Maples Group assists Biohaven in managing investments led by Oberland Capital.
Published at 15 May 2025
Healthcare juggernaut Oberland Capital pumps $600 million into Biohaven Ltd.
In a game-changing move, international law firm Maples and Calder, under The Maples Group, has been the legal powerhouse orchestrating the $600 million investment deal between private investment firm Oberland Capital and biopharmaceutical company Biohaven Ltd.
The blazing-hot Biohaven-Oberland Capital dance floor was not without its all-stars. The corporate dream team from Maples and Calder included BVI managing partner Chris Newton, Cayman Islands partner Louise Cowley, BVI associate Chloe Harris, and Cayman Islands associate Kimberly Robinson. All of them working harmoniously alongside Biohaven's U.S. counsel, international law firm Covington & Burling LLP.
Biohaven Ltd., a BVI-incorporated pharmaceutical dynamo, is on a mission to commercialise, develop, and discover treatments spanning immunology, neuroscience, and oncology.
Oberland Capital, a global healthcare trailblazer, has handed over a whopping $600 million to Biohaven, earmarked for financing ongoing clinical trials. The funds will be repaid via royalty payments on future net sales of Troriluzole, a new chemical entity that modulates glutamate, paving the way for groundbreaking treatments.
Matt Buten, Biohaven's CFO, expressed his excitement: "Securing Oberland Capital's backing is a testament to our company's commitment to pioneering rare disease treatments. With their extraordinary track record in steering healthcare companies through eventful product launches, we're thrilled to have them on board. This flexible, long-term, non-dilutive financing agreement validates the immense potential of Troriluzole and our diverse portfolio of five innovation-packed platforms."
Covington & Burling LLP, Biohaven's U.S. legal advisor, played a pivotal role in the negotiation, structuring, and closing of the investment agreement with Oberland Capital Management LLC. They offered legal guidance on the issuance of senior secured notes, the terms tied to milestone payments, and royalties connected to the clinical development and potential commercialisation of Biohaven's magic bullet, Troriluzole.
All in all, Covington & Burling LLP, acting as Biohaven's U.S. legal counsel, ensured the company's interests were protected, facilitating the successful execution of the substantial financing deal to back Biohaven's ongoing clinical trials and future commercialisation endeavours. Meanwhile, Cooley LLP was the legal advisor to Oberland Capital.
In this financial landscape, Oberland Capital, renowned for its healthcare investments, has pledged $600 million towards Biohaven Ltd., a company revolving around science and health-and-wellness, particularly within the realms of immunology, neuroscience, and oncology. Financing from finance giants like Oberland Capital will aid Biohaven in funding clinical trials, with potential returns from royalty payments that could be used towards future financial ventures, thus intertwining the domains of finance and healthcare.
